Latest GALILEO CRVO Stories
EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
TARRYTOWN, N.Y., June 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion
TARRYTOWN, N.Y., Feb. 24, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S.
Word of the Day
The word 'postliminy' comes from a Latin word meaning 'threshold'.